Novalis Shaped Beam Radiation Treatment for Craniopharyngiomas.
- Author:
Gi Taek YEE
1
;
Seong Rok HAN
;
Sang Won YOON
;
Chan Young CHOI
;
Dong Joon LEE
;
Choong Jin WHANG
Author Information
1. Department of Neurosurgery, Ilsan Paik Hospital, College of Medicine, Inje University, Goyang, Korea. gtyee@ilsanpaik.ac.kr
- Publication Type:Original Article
- Keywords:
Craniopharyngioma;
Shaped beam radiation treatment;
Optic neuropathy
- MeSH:
Craniopharyngioma*;
Follow-Up Studies;
Humans;
Magnetic Resonance Imaging;
Optic Nerve Diseases;
Recurrence;
Vision Disorders
- From:Journal of Korean Neurosurgical Society
2006;40(4):245-248
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To evaluate the effectiveness of Novalis shaped beam radiation treatment as an adjuvant treatment in patients with craniopharyngiomas. METHODS: We reviewed 8 patients with craniopharyngiomas who had recurring tumors during follow-up or had residual lesions after primary surgery. Three of 8 patients were found to have recurrence after gross total excision of the tumor and 5 patents had residual lesions after subtotal resection. All patients were treated with fractionated stereotactic radiation treatment(FSRT) using Novalis system. The mean age of patients was 28 years (range 16~52). The median irradiation dose per fraction was 1.7Gy (range 1.7~2.0). The median fraction number was 23 (range 15~25), and the median total dose was 39.1Gy (range 25.5~42.5). Follow-up included MR imaging, and ophthalmologic and endocrine examinations. RESULTS: The median follow-up period was 23 months (range 12~43). The local tumor control rate was 87.5%. One patient had a recurring tumor, in which cystic change developed 2 months after FSRT. Four patients showed a decrease in size of their tumor, while 3 patients remained stable. Seven out of 8 patients had hormonal dysfunction that remained unchanged after initial surgery. No further progression of visual impairment was observed. CONCLUSION: FSRT using Novais system is effective and safe for the treatment of recurring or residual craniopharyngiomas without toxicity like optic neuropathy.
